Full-Time

Account Manager

Multiple Teams

Posted on 8/27/2025

LGC Group

LGC Group

1,001-5,000 employees

Sells oligos, probes, primers, viral materials

No salary listed

Alexandria, MN, USA

Hybrid

The position is remote in the designated region (TX, CO, NM, OK, MO, KS, MS, AL, LA, AK) with 50% travel to customer sites.

Category
Sales & Account Management (1)
Requirements
  • Bachelor's degree or equivalent experience in biological or life sciences, business management, or related field.
  • Emphasis in molecular and cell biology and related applications preferred (sales or wet-lab experience).
  • 2+ years of demonstrated sales success within the life sciences industry.
  • Established record of success in handling both new and established accounts, demonstrating expertise in strategic selling and managing large accounts.
  • Proficiency in managing complex sales processes, including territory planning, prospecting, discovery, analysis, solution design, presentation, negotiation, and closing.
  • Excellent communication skills, including strong listening, verbal, and written communication abilities.
  • Strong computer skills required, with a working knowledge of Microsoft Office suite of products, particularly Word, Excel, and PowerPoint.
  • Ability to travel as needed.
Responsibilities
  • Pipeline Management: Generate and qualify a robust pipeline of prospects, vital for the company to attain future goals. This involves coordinated support of marketing strategies with the Global Marketing Director and other team members to generate leads, followed by thorough qualification of potential engagements. Maintaining systems and updating prospect records are integral to ensuring accurate pipeline visibility at all corporate levels.
  • Lead strategic sales process to achieve new sales, networking across levels, facilitating sessions, negotiating, and adhering to corporate guidelines for outcomes.
  • Demonstrate strategic selling abilities to grasp clients' needs and suggest LGC Diagnostics & Genomics solutions to tackle scientific, automation, and business issues.
  • Manage client relationships as the main executive for LGC Diagnostics & Genomics accounts, focusing on revenue growth and new opportunities. Lead account-specific teams, improve client satisfaction, identify revenue opportunities, and request references.
  • Industry and Product Knowledge: Develop and uphold a profound comprehension of industry trends, client operations, and competitive offerings to strategically showcase LGC Diagnostics & Genomics products. Capably represent LGC in different customer-facing capacities, such as sales meetings, client engagements, media interactions, and industry gatherings.
  • Business Development: Support Product Management and Business Development efforts by identifying and evaluating new business and market opportunities, which may entail interaction with existing clients and prospects.
  • Salesforce.com Reporting: Provide timely sales and pipeline inputs as necessary to support the reporting of leading and lagging indicators. Ensure accurate, complete, and timely expense reporting. Facilitate account review meetings for strategic accounts and maintain timely and accurate reporting of sales data in the company's CRM system.
  • Additional Responsibilities: Show adaptability and teamwork when meeting the business requirements – both internally and externally – by handling key corporate projects as directed by leadership.
Desired Qualifications
  • Previous exposure to CRM software, especially SalesForce.com, is crucial for pipeline and account management.
  • Strong product knowledge and sales experience in Life Science products, especially in nucleic acid extraction/purification, PCR, qPCR, and NGS workflows. Experience selling into regulated markets, such as diagnostic kit manufacturers, is highly desirable.
  • Experience in managing capital equipment and/or large opportunities ($100K+).
  • Customer-focused and responsive, with a demonstrated ability to build critical relationships.
  • Passionately? wait, let's correct
  • Passionate about discovering and developing solutions for complex process problems faced by clients.
  • Collaborative and oriented towards teamwork, demonstrating a consistent history of exerting influence in a guiding and constructive fashion.
  • Exhibits professional discretion, tact, and friendliness when communicating with internal and external clients, managing confidential information.
  • Demonstrates independence: able to start and lead projects while acknowledging when to involve collaborators.
  • Possesses creative problem-solving skills and the ability to communicate effectively to achieve consensus and facilitate decision-making within a matrix environment.
  • Adaptable and willing to take on multiple new tasks and responsibilities while effectively managing and prioritizing within a dynamic work environment.
  • Goal-oriented and efficient in meeting targets on time and within budget.
  • Embraces and embodies LGC’s core values: Passion, Curiosity, Integrity, Brilliance, and Respect.

LGC Group provides life-sciences tools and services worldwide, including oligo components, probes, primers, recombinant viral materials, and proficiency-testing schemes for food safety. Its products support vaccine development, diagnostics, and therapies through mass spectrometry, immunoassays, and nucleic acid chemistry. It differentiates itself with a broad catalog of high-quality tools plus global proficiency-testing services and a wide customer base across diagnostics, healthcare, and pharma. Its goal is to improve healthcare outcomes and help create safer vaccines and treatments by delivering reliable tools and quality services.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

London, United Kingdom

Founded

1841

Simplify Jobs

Simplify's Take

What believers are saying

  • ChromaDex acquisition February 2026 adds 3,000 phytochemical standards boosting North America sales.
  • Irish Horseracing Board renews LGC contract through 2027 for equine anti-doping analysis.
  • CAD$100 million Canada synthesis center expands pharma research chemical capacity.

What critics are saying

  • Merck KGaA erodes LGC market share with bundled CRMs at lower prices by Q1 2027.
  • WADA 2026 protocol causes Fordham lab to lose 30% human sports testing to NSF by Q4 2026.
  • USFDA revokes Lexington accreditation May 2026, forfeiting $50M horse racing contracts to Eurofins.

What makes LGC Group unique

  • LGC's Informed-Sport certifies 440 products against 250+ banned substances using ISO 17025 labs.
  • Lexington facility expanded November 2016 for equine doping control and US supplements testing.
  • LoGiCal portfolio offers 3,000+ toxicology reference standards since 2012 launch.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Remote Work Options

Company News

LGC Group
Feb 26th, 2026
LGC Group strengthens its reference material portfolio and North American reach with the acquisition of the ChromaDex Reference Standards business

LGC Group strengthens its reference material portfolio and North American reach with the acquisition of the ChromaDex Reference Standards business. The acquisition further enhances LGC's ability to support pharmaceutical, food, and testing laboratories with trusted reference materials that underpin safety, quality, and regulatory confidence. London, UK, 26 February 2026. LGC Group, a global leader in life sciences, diagnostics, and analytical solutions, today announced the acquisition of the ChromaDex Reference Standards portfolio from Niagen Bioscience (NASDAQ: NAGE). The acquisition expands LGC's reference materials offering and strengthens its commercial reach across North America. The acquisition brings an established portfolio of phytochemical reference materials for the dietary supplements industry into LGC, enabling direct engagement with a broad base of laboratory customers and strengthening LGC's ability to support pharmaceutical companies, testing laboratories, and food producers operating in regulated markets. Bruno Rossi, EVP & General Manager, LGC Standards, said: "The ChromaDex standards portfolio further enhances LGC's ability to support our pharmaceutical customers, testing laboratories, and food producers. Building on LGC's position as a world leader in reference materials and analytical standards, this acquisition expands our North American commercial reach and further supports customers in generating reliable data that safeguards product integrity and confidence across global supply chains." For over 25 years, the ChromaDex Reference Standards portfolio has been built on deep expertise in phytochemical characterisation and analytical verification. The portfolio includes over 3,000 phytochemical reference materials, spanning major classes such as alkaloids, flavonoids, terpenes, carotenoids, organic acids, stilbenoids, vitamins, and select botanicals and plant-based compounds. These materials are widely used to support ingredient verification, method development, authenticity testing, contamination detection, and routine quality control across complex global supply chains. Rob Fried, CEO of Niagen Bioscience, remarked, "This transaction reflects our disciplined focus on what we do best - advancing NAD+ science and delivering clinically proven, patented Niagen(R) solutions across consumer and clinical channels. Selling Reference Standards to LGC is a meaningful step in simplifying our business and ensuring we are allocating capital and talent toward the highest-impact opportunities for shareholders." The acquisition of the ChromaDex Reference Standards portfolio demonstrates LGC's commitment to providing trusted reference materials and measurement solutions that reinforce product safety, quality, and regulatory confidence, advancing its mission of Science for a Safer World. LGC is a global leader in life sciences, diagnostics, and analytical solutions. LGC Group work with partners around the world to address some of society's most important challenges, from diagnosing disease and enabling new treatments to supporting food security and protecting public health. Its science supports discovery, enables better health outcomes and helps safeguard the integrity of food, water, medicines and the environment. Every day, LGC Group provide the components, standards and services that laboratories, manufacturers and regulators rely on to make confident, evidence-based decisions. With operations in 14 countries and more than 180 years of scientific expertise, its work supports public health and sustainability at a global scale. From improving the accuracy of medical testing and verifying the safety of food products, to helping scientists develop the next generation of medicines, its solutions are trusted by customers in more than 170 countries. For further information please contact: Customer contact: Richard Pembrey Sales Director, LGC Standards +1 603 851 2834 Media contact: Magda Bartoszewicz Director Corporate Brand and Communications, LGC Group +44 7408 850 514

CHEManager
Sep 12th, 2025
LGC Opens $100 Million Pharma Synthesis Center in Canada

LGC Group has inaugurated a CAD$100 million (€61.5 million) Organic Chemistry Synthesis Centre of Excellence in Vaughan, canada, significantly expanding global capacity for advanced research chemicals to support the pharmaceutical and life sciences sectors.

Graham B Jackson (Aust) Pty Ltd
Apr 15th, 2025
Ensuring Precision in Analysis: Graham B Jackson Pty Ltd Supply of LGC Certified Reference Materials

Graham B Jackson Pty Ltd (GBJPL), an Australian leader in reference materials, partners with the globally renowned LGC Group to supply high-quality CRMs to laboratories across the country.

Health Technology Insights
Apr 4th, 2025
Laboratory Proficiency Testing Market to Reach $2.1 Billion by 2030

For example, LGC Group introduced a proficiency testing (PT) service in April 2020 that uses nucleic acid amplification testing to identify SARS-CoV-2 (COVID-19).

Investors in Healthcare
Jan 10th, 2025
UK: LGC appoints Joydeep Goswami as president and CEO

UK-based LGC, an international life sciences measurement and tools company, has appointed Joydeep Goswami as president and CEO, succeeding Euan O'Sullivan, who decided to step down from his role in early 2024 after fourteen years of service.

INACTIVE